Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 4: 770 - 776

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.04.007

Original Articles

Effect of Jiawei Huangqi Guizhi decoction (加味黄芪桂枝汤) on the expression of gastrin content and phosphatidylinositol 3-kinase/ protein kinase B/mechanistic target of rapamycin complex 2 signalling pathways in rats with chronic atrophic gastritis

  • Xia ZHOU ,
  • Kaiqing LIANG ,
  • Weigang CHEN ,
  • Yong CAO ,
  • Hongdong DUO ,
  • Qiangbin LI ,
  • Yun AN
Expand
  • 1 Department of Gynecology and Internal Medicine, Panyu Hospital of Traditional Chinese Medicine, Guangzhou 511400, Chin
    2 Panyu Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
    3 College of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China
AN Yun, Digestive internal medicine, Panyu District Traditional Chinese Medicine Hospital, Guangzhou 511400, China. anyun_2022@163.com,Telephone: +86-20-85926915, +86-20-85926913

Received date: 2024-04-22

  Accepted date: 2024-09-23

  Online published: 2025-07-25

Supported by

Guangzhou Science and Technology Bureau Research Fund: the Mechanism of Action of Huangqi Guizhi Decoction on Precancerous Lesions in Cag Rats was Studied based on the Phosphatidylinositol 3-Kinase-Protein Kinase B-Mechanistic Target of Rapamycin Complex 2 Pathway(202102080643);Guangzhou Traditional Chinese Medicine and Integrative Medicine Research Project: Observation on the Therapeutic Effect of Wenyang Jianpi Ointment on Chronic Atrophic Gastritis of Spleen and Stomach Weakness Type and Study on its Regulatory Effect on Transforming Growth Factor Beta 3(20222A010079);Panyu District Science and Technology Project: the Mechanism by which the Modified Huangqi Guizhi Decoction Regulates the Transforming Growth Factor-β3 Signaling Pathway to Improve Precancerous Lesions in Rats with Chronic Atrophic Gastritis(2020-Z04-025)

Fold

Abstract

OBJECTIVE: To investigate the effects of Jiawei Huangqi Guizhi decoction (加味黄芪桂枝汤) on chronic atrophic gastritis (CAG) in rats and its modulation of the phosphatidylinositol 3-kinase/protein kinase B/ mechanistic target of rapamycin complex 2 (PI3K/Akt/ mTORC2) signaling pathway.

METHODS: CAG was induced in rats and treated with high-, medium-, or low-dose Jiawei Huangqi Guizhi decoction. Gastric histopathology was observed by hematoxylin and eosin staining. Serum levels of gastrin, PI3K, Akt, and mTORC2 were detected by enzyme-linked immunosorbent assay. Gene and protein expression levels were analyzed by reverse transcription polymerase chain reaction and western blot.

RESULTS: The decoction alleviated gastric mucosal injury, reduced inflammation, and restored epithelial structure. It regulated PI3K, Akt, and mTORC2 expression at both mRNA and protein levels.

CONCLUSION: Jiawei Huangqi Guizhi decoction may prevent CAG progression by improving gastric tissue and modulating the PI3K/Akt/mTORC2 signaling pathway.

Key words： gastrins; PI3K; Akt; mechanistic target of rapamycin complex 2; signal transduction; pathology; Jiawei Huangqi Guizhi decoction

Cite this article

Xia ZHOU , Kaiqing LIANG , Weigang CHEN , Yong CAO , Hongdong DUO , Qiangbin LI , Yun AN . Effect of Jiawei Huangqi Guizhi decoction (加味黄芪桂枝汤) on the expression of gastrin content and phosphatidylinositol 3-kinase/ protein kinase B/mechanistic target of rapamycin complex 2 signalling pathways in rats with chronic atrophic gastritis[J]. Journal of Traditional Chinese Medicine, 2025 , 45(4) : 770 -776 . DOI: 10.19852/j.cnki.jtcm.2025.04.007

References

1. Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1:national cancer statistics. J Natl Cancer Inst 2021; 113: 1648-69.
2. Jiana Z. WHO's latest cancer report: breast cancer replaces lung cancer as the world's largest cancer China becomes the country with the largest number of new cancers. Everyone's Health 2021; 3: 11.
3. Spleen and Stomach Disease Branch of Chinese Medicine Association. Diagnosis and treatment of chronic atrophic gastritis with Traditional Chinese Medicine (Shenzhen, 2009). Zhong Xi Yi Jie He Xiao Hua Za Zhi 2010; 18: 345-9.
4. Fang JY, Du YQ, Liu WZ, et al. Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis 2018; 19: 182-203.
5. An Y, Chen WG, Li QB, Du HD. Observation on the effect of modified Huangqi Guizhi decoction in treating chronic atrophic gastritis of deficiency cold of spleen and stomach type. Zhong Guo She Qu Yi Shi 2023; 39: 84-6.
6. Lian YH, Zhao B, Zhou B. Clinical observation on the treatment of chronic atrophic gastritis with Wenyang Jianpi decoction for spleen and stomach weakness. Zhong Yi Yao Xue Bao 2017; 32: 2814-7.
7. Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 2016; 67: 11-28.
8. Li J, Zhou HJ. Progress of PI3K/Akt signaling pathway in tumor research. Dong Nan Da Xue Xue Bao Yi Xue Ban 2014; 33: 392-5.
9. Tapia O, Riquelme I, Leal P, et al. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch 2014; 465: 25-33.
10. Su LZ, Jiao LJ, Xu L. Clinical research progress of Chinese medicine in the treatment of gastric cancer. Lin Chuang Yi Xue 2021; 42: 335-9.
11. Yan ZP, Xu TT, An ZT, Lu WL. Effect of Spleen and Qi Formula on PI3K-Akt signaling pathway in gastric tissue in rats with chronic atrophic gastritis. Zhong Yi Za Zhi 2019; 34: 4800-4.
12. Zhou KJ, Hu N, Wu XY, Lin Q. The expression and clinical significance of TGF-β, PD-L1 and PI3K protein in gastric carcinoma. Xian Dai Zhong Liu 2022; 30: 2394-9.
13. Xu SY. Pharmacological experimental methodology. Beijing: People's Medical Publishing House, 2002: 103-4.
14. Chinese Society of Gastroenterology, Gastroenterology Group. Chinese consensus opinions on chronic gastritis (2017, Shanghai). Zhong Guo Xiao Hua Za Zhi 2017; 37: 721-38.
15. Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev 2016; 45: 87-96.
16. Wang T, Seah S, Loh X, et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget 2016; 7: 2532-44.
17. Singh SS, Yap WN, Arfuso F, et al. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: a reality for personalized medicine? World J Gastroenterol 2015; 21: 12261-73.
18. Song HN, Yu JN, Lu JH, Chen L, Lin HY. Akt-Mdm2-P53 mechanism of atrophic gastritis in the treatment of chronic atrophic gastritis in rats. Zhong Guo Lao Nian Xue Za Zhi 2020; 40: 1308-12.
19. Xia Z, Gao T, Zong Y, Shen XQ. Evaluation of subchronic toxicity of GRD081, a dual PI3K/mTOR inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and beagle dogs. Food Chem Toxicol 2013; 62: 687-98.
20. Tabe Y, Tafuri A, Sekihara K, Yang H, Konopleva M. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets 2017; 21: 705-14.
21. Takeuchi CS, Kim BG, Blazey CM, et al. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). J Med Chem 2013; 56: 2218-34.
22. Zhang H, Bao XJ, Dai CX, Zhu LT. Advances in PI3K/AKT/ mTOR signaling pathway in nonfunctioning pituitary adenomas. Zhong Guo Yi Xue 2015; 47: 3874-6.
Options
Outlines

/

〈 〉